Ticker

INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission INBS implements enhanced security architecture to protect test integrity and donor data, strengthening upcoming FDA 510(k) submission

Study results finalized on schedule  support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference testing NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive…

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received European Patent EP3752831, related to contextualizing fingerprint chemical analysis with fingerprint deposition volume. The grant marks the Company's eighth European patent,…

HealthEquity (NASDAQ: HQY - Get Free Report) and Intelligent Bio Solutions (NASDAQ: INBS - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation. Profitability This table compares HealthEquity and Intelligent Bio

Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026